KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Investment Income (2019 - 2025)

Historic Non Operating Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$1.0 million.

  • Royalty Pharma's Non Operating Investment Income rose 8888.89% to -$1.0 million in Q4 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 36666.67%. This contributed to the annual value of -$6.0 million for FY2024, which is 16200.87% down from last year.
  • As of Q4 2025, Royalty Pharma's Non Operating Investment Income stood at -$1.0 million, which was up 8888.89% from $4.0 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Non Operating Investment Income ranged from a high of $71.8 million in Q2 2022 and a low of -$17.0 million during Q3 2021
  • Its 5-year average for Non Operating Investment Income is $4.2 million, with a median of -$990000.0 in 2022.
  • Data for Royalty Pharma's Non Operating Investment Income shows a peak YoY increase of 386139.34% (in 2022) and a maximum YoY decrease of 92083.33% (in 2022) over the last 5 years.
  • Royalty Pharma's Non Operating Investment Income (Quarter) stood at -$96000.0 in 2021, then plummeted by 920.83% to -$980000.0 in 2022, then tumbled by 785.71% to -$8.7 million in 2023, then dropped by 3.69% to -$9.0 million in 2024, then soared by 88.89% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q4 2025, $4.0 million for Q3 2025, and -$2.0 million during Q2 2025.